In phase III cancer trials, what is the primary objective?

• A. Evaluate the efficacy of the new agent and validate toxicity and dosage data
• B. Determine the maximum tolerated dose of the investigational drug
• C. The value of the new agent in relation to existing treatments
• D. The interactions of the new agent with other drugs or population groups

Answer: (C)

In Phase III cancer trials, the main goal is to determine whether the new treatment offers value compared to the current standard therapy. This means testing the new option in a larger, randomized population to see if it provides better outcomes while maintaining acceptable safety. The emphasis is on comparative effectiveness—does the new agent improve key outcomes such as overall survival, progression-free survival, response rates, or quality of life relative to what is already used?

This focus on comparing against the standard of care is what sets Phase III apart from earlier phases. Phase I concentrates on safety and finding the right dose, often in small groups. Phase II looks for preliminary signals of efficacy and further safety but doesn’t usually compare against the standard treatment. Studies of drug interactions or subgroup effects belong more to pharmacology or exploratory analyses rather than establishing comparative value as the primary objective.